AstraZeneca says the COVID-19 vaccine it developed in cooperation with Oxford University was 79-percent effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru, paving the way for its long-awaited application for US approval.
The vaccine was found to be 100 percent effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, as it released results of the late-stage human trial study of more than 32,000 volunteers across all age groups.
The study found the vaccine effective across all ages, including older people, which previous studies in other countries had raised concerns over.
Although AstraZeneca’s vaccine has been authorised in more than 50 countries, it has yet to receive the green light in the US.
This will also help allay safety concerns that disrupted its use in the European Union after a small number of cases of rare blood clots in people who have received the shot were reported.
After more than two dozen countries briefly halted its use, many European countries have resumed using the shot in their inoculation programmes after a regional regulator said it was safe, while several country leaders are also taking the vaccine to boost confidence.